Consistently, the KEYNOTE‐811 study confirmed that adding pembrolizumab to trastuzumab and chemotherapy achieved an objective response rate (ORR) of 74.4% and markedly reduced tumor size in patients with Her2‐positive gastric cancer/gastroesophageal junction adenocarcinoma.[7] Therefore, the targeting of Her2 and PD‐1 has huge prospects for clinical application to overcome the resistance of Her2‐positive gastric cancer to trastuzumab. The gene discussed is PDCD1; the disease is gastric cancer.